Because
chronic respiratory diseases like asthma, chronic obstructive pulmonary disease
(COPD), and respiratory disorders are more common, there is an increasing need
for digital dosage inhalers. Demand for the product is also fueled by the
growing requirement to efficiently track the day and time of dosage, which
encourages cooperative treatment between clinics and patients. Demand for
products is also being driven by the growing elderly population, who are
suffering from both moderate and severe respiratory illnesses. For instance,
between 1990 and 2019, the percentage of the population 65 years of age and
older climbed from 6% to 9%, according to the United Nations Department of
Economic and Social Affairs.
Trends in the Digital Dose
Inhaler Market
According
to our research analysts, the following are the main key trends influencing the
digital dose inhaler market:
Over the course of the forecast period, dry powder inhalers, or DPIs, are anticipated
to play a significant role in the market's growth.
Devices called dry powder inhalers are used to administer medication in the
form of dry powder to the lungs. The prevalence of chronic respiratory
conditions including COPD, asthma, etc., and the rising demand for
technologically advanced features in respiratory devices are the main drivers
of the dry powder inhaler market's expansion.
DPI use has increased due to issues with medication irritation incidents
brought on by propellant components such chlorofluorocarbons (CFCs) in MDI.
The digital
dose inhaler market is estimated to be valued at US$ 64.33 Bn in 2024 and is expected to exhibit a CAGR of 19% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the
Digital
Dose Inhaler Market Growth are 3M, AstraZeneca, GLENMARK PHARMACEUTICALS
LTD., Novartis AG, Sensirion AG, Propeller Health, OPKO Health, Inc., Teva
Pharmaceutical Industries Ltd., BEXIMCO Pharmaceuticals, GSK plc., Mundhipharma
International, Honeywell International Inc., and Veranex. Key players are
actively investing in R&D to develop smart connected inhalers integrated
with mobile apps and sensors. This allows real-time monitoring of medication
use and respiratory health parameters.
Growing incidence of asthma and COPD worldwide is driving the demand for
digital dose inhalers. As per WHO, around 235 million people suffer from asthma
globally. Digital inhalers ensure correct inhalation technique and drug
adherence for long-term management of respiratory diseases. Technological
advancements are allowing integration of digital dose inhalers with artificial
intelligence and cloud computing. This enables predictive analysis of disease
progression and risk of exacerbations based on medication use patterns.
Market Trends
Increasing preference for smart devices - Growing popularity of smartphones and
wearables is driving demand for connected digital inhalers that can securely
transmit health data to mobile apps. This allows remote monitoring by
physicians.
Bluetooth and mobile app connectivity - Leading players are focusing on
developing digital inhalers integrated with Bluetooth to facilitate wireless
transmission of medication use data to companion mobile apps for real-time
tracking and alerts.
Market Opportunities
Integration with electronic health records - Growing emphasis on digitization
of healthcare presents an opportunity for digital dose inhaler manufacturers to
develop solutions integrated with doctors' EHR systems for automated updates on
patients' respiratory health status.
Adoption in developing countries - Rising air pollution levels and growth of
medical reimbursement programs in developing nations will drive the uptake of
digital dose inhalers for effective management of respiratory diseases.
Impact of COVID-19 on Digital Dose
Inhaler Market
The COVID-19 pandemic has significantly impacted the growth of the digital dose
inhaler market. During the initial phase of the pandemic, it witnessed a
decline due to supply chain disruptions and lockdowns enforced across various
countries. This led to a decrease in production and sales volumes. However, as
the pandemic intensified globally, the demand and adoption of digital dose
inhalers increased substantially. Factors such as growing awareness regarding
respiratory diseases caused due to COVID-19 infections, increased focus on
devices facilitating remote monitoring of patients, and need for adherence and compliance
to medication drove the growth of this market. Furthermore, with movement
restrictions in place, telemedicine emerged as an effective solution, enabling
virtual consultation between healthcare providers and patients. This helped
drive the utilization of connected digital dose inhalers which could transmit
critical usage data to physicians remotely.
Moreover, manufacturers ramped up their production capacities and focused on
ensuring an uninterrupted supply of digital dose inhalers to cater to the
growing customer demand. Several companies also received emergency use
authorization and approvals for their connected inhalers from regulatory
bodies, which further propelled market growth during the pandemic. Overall,
despite initial disruptions, the COVID-19 outbreak augmented the need for
devices enabling remote patient monitoring and facilitated the increased
adoption of digital dose inhalers globally on a long-term basis.
North America dominates the digital dose inhaler market in terms of value. This
is attributed to factors such as high prevalence of chronic respiratory
disorders, robust presence of leading players, favorable reimbursement
policies, and increasing preference for self-administered medication. Moreover,
growing investments by both public and private sectors to promote digital
health technologies also support the region's large market share. The Asia
Pacific region is projected to witness the fastest growth during the forecast
period owing to large patient population, rising healthcare expenditures,
increasing incidence of respiratory diseases, and favourable government
initiatives to modernize healthcare infrastructure in several emerging
countries.
Get
more insights on Digital
Dose Inhaler Market
Comments
Post a Comment